




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61L 27/00, 27/22	A1	(11) International Publication Number: WO 00/25838 (43) International Publication Date: 11 May 2000 (11.05.00)
(21) International Application Number: PCT/US99/25955		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 4 November 1999 (04.11.99)		
(30) Priority Data: 9800796 4 November 1998 (04.11.98) BE		
(71) Applicant (for all designated States except US): BAXTER INTERNATIONAL INC. [CA/US]; One Baxter Parkway, Deerfield, IL 60015 (US).		
(72) Inventors; and		
(75) Inventors/Applicants (for US only): DELMOTTE, Yves [BE/BE]; 36, rue de la Fontaine, B-7333 Tertre (BE). BELOT, Nathalie [BE/BE]; 6, rue de Saintes, bte 2, B-1400 Nivelles (BE). VERMEULEN, Pierre [BE/BE]; 64, avenue des Alouettes, B-1428 Lillois (BE). TASIAUX, Nicole [BE/BE]; 11, avenue des Bouleaux, B-1170 Bruxelles (BE).		
(74) Agents: GUTHRIE, Janice et al.; Baxter Healthcare Corporation, P.O. Box 15210, Irvine, CA 92623-5210 (US).		

(54) Title: ELEMENT PROVIDED WITH A FIBRIN LAYER, PREPARATION AND USE THEREOF

(57) Abstract

An element provided with a layer based on fibrin- or fibrinogen-containing material, said element comprising (a) a hydrophobic or substantially hydrophobic support, which has a porous part with a thickness of 0.1 to 5 mm, and whose pores, extending across its thickness have a node spacing of 5 to 100 μ m, one face of said porous part being treated with a compound based on fibrin and/or a fibrinogen-containing material, and (b) a fibrin-based layer covering said treated surface of the support, characterized in that said fibrin-based layer is substantially uniform and homogeneous on said treated surface, and that the fibrin layer and at least the face of the support in contact with the fibrin layer are substantially free of fibrinogen.